MedPath

POLYSAN Scientific & Technological Pharmaceutical Company

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

23

Active:0
Completed:15

Trial Phases

3 Phases

Phase 1:1
Phase 2:5
Phase 3:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
7 (53.8%)
Phase 2
5 (38.5%)
Phase 1
1 (7.7%)

Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

Recruiting
Conditions
Viral Enteric Infection
Interventions
Drug: Reamberin® solution for infusion, 1.5 %
First Posted Date
2025-07-15
Last Posted Date
2025-07-15
Lead Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Target Recruit Count
300
Registration Number
NCT07066540
Locations
🇷🇺

South Ural State Medical University, Chelyabinsk, Russian Federation

🇷🇺

Khimki Clinical Hospital, Khimki, Russian Federation

🇷🇺

Kuban State Medical University, Krasnodar, Russian Federation

and more 5 locations

REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis

Phase 2
Recruiting
Conditions
Diabetic Ketoacidosis
Interventions
Drug: Reamberin
Drug: Placebo
First Posted Date
2025-05-02
Last Posted Date
2025-06-24
Lead Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Target Recruit Count
312
Registration Number
NCT06955416
Locations
🇷🇺

Kuzbass Clinical Hospital of Emergency Medical Care named after M.A. Podgorbunsky, Kemerovo, Russian Federation

🇷🇺

State Budgetary Institution of Healthcare of the Arkhangelsk Region "First City Clinical Hospital named after E.E. Volosevich", Arkhangelsk, Russian Federation

🇷🇺

Regional budgetary healthcare institution "Ivanovo regional clinical hospital", Ivanovo, Russian Federation

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome

Recruiting
Conditions
Ischemic Stroke
First Posted Date
2024-12-16
Last Posted Date
2025-04-06
Lead Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Target Recruit Count
90
Registration Number
NCT06735898
Locations
🇷🇺

Brain Institute Clinic, Ekaterinburg, Sverdlovsk region, Russian Federation

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Recruiting
Conditions
Stroke, Acute
Stroke, Ischemic
Interventions
First Posted Date
2024-07-23
Last Posted Date
2025-04-18
Lead Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Target Recruit Count
562
Registration Number
NCT06514976
Locations
🇷🇺

"Ivanovo Regional Clinical Hospital", Ivanovo, Russian Federation

🇷🇺

Kazan State Medical University, Kazan, Russian Federation

🇷🇺

State Autonomous Institution of Health Interregional clinical diagnostic center, Kazan, Russian Federation

and more 14 locations

Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection

Completed
Conditions
Acute Respiratory Viral Infection
Interventions
Drug: Cycloferone
First Posted Date
2024-02-29
Last Posted Date
2024-12-16
Lead Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Target Recruit Count
742
Registration Number
NCT06286254
Locations
🇷🇺

Clinic Zvezdnaya, Saint Petersburg, Russian Federation

🇷🇺

Medical center Astarta, Saint Petersburg, Russian Federation

🇷🇺

Medical Center Energiya Zdoroviy, Saint Petersburg, Russian Federation

and more 10 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.